Aurobindo Pharma Q3 FY23 net profit down 18.7% at Rs 491 Crores
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
A centralised kitchen which provides 5,000 breakfast meals per day is to be started at Perumallapuram, Kakinada, Andhra Pradesh
With the implementation of this project, a total of 1,030 acres of cultivable land can be irrigated per crop cycle
The brand is now available pan-India through their distribution partner
The drug will be marketed under the brand name Molnaflu
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Subscribe To Our Newsletter & Stay Updated